Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Addrenex licenses new narcolepsy drug
Addrenex Pharmaceuticals, a specialty pharmaceutical company, has signed an agreement to license a new drug for the treatment of narcolepsy, as well as other neurologic and psychiatric conditions.
Addrenex Pharmaceuticals, a specialty pharmaceutical company, has signed an agreement to license a new drug for the treatment of narcolepsy, as well as other neurologic and psychiatric conditions.
Lipoxen, a UK-based developer of drug and vaccine delivery systems, has received funding to apply its ImuXen technology to enhance the performance of malaria vaccine candidates. The PATH
ViraCor Laboratories, a provider of molecular diagnostic testing for infectious diseases, has launched a new cytomegalovirus antiviral resistance test that reportedly provides diagnosis days faster than other tests
Rafael Medical Technologies, a developer of intravascular devices, has received marketing clearance from FDA for its SafeFlo vena cava filter. The clearance is for the permanent implantation of
US-based Competitive Technologies has reported that its bone nanoparticle biomaterial technology has been issued a third patent supporting the first two patents and providing additional claims regarding the
Belgium-based biopharmaceutical company UCB has received FDA approval for Cimzia, the only PEGylated anti-tumor necrosis factor, for the treatment of adult patients with moderately to severely active rheumatoid
AxioMed Spine has received CE Mark approval for its Freedom lumbar disc, an elastomeric total spinal disc replacement device. The CE Mark approval was received from the notified
Canada-based Oncolytics Biotech has successfully completed patient enrollment in its multi-centre Phase II clinical trial to evaluate the intravenous administration of Reolysin in patients with various sarcomas that
The National Heart, Lung, and Blood Institute of the National Institutes of Health has stopped enrollment into a clinical trial testing the effects of highly concentrated saline solutions
NovImmune, a Switzerland-based biotechnology company, has raised $54.8m to take back control of its lead compounds, NI-0401 and NI-0501, a fully human monoclonal antibody to CD3 and interferon-gamma,